Working... Menu
Trial record 8 of 36 for:    fetal alcohol children

Assess the Effectiveness of Atomoxetine in Children With Fetal Alcohol Syndrome and ADD/ADHD (B4Z-MC-X017)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00417794
Recruitment Status : Completed
First Posted : January 4, 2007
Last Update Posted : April 10, 2017
Mark L. Wolraich, M.D.
Eli Lilly and Company
Information provided by (Responsible Party):
University of Oklahoma

Brief Summary:
The purpose of this study is to determine if atomoxetine hydrochloride improves inattention, hyperactivity, and impulsivity problems in children exposed to alcohol during birth.

Condition or disease Intervention/treatment Phase
Fetal Alcohol Syndrome Attention Deficit Disorder With Hyperactivity (ADHD) Attention Deficit Disorder (ADD) Drug: Strattera Drug: Placebo Phase 1

Detailed Description:
Abnormalities of attention, function, and activity level in children exposed to alcohol in utero share similarities and differences to children who do not have alcohol exposure. Previous psychological studies have examined either core attention deficit hyperactivity disorder (ADHD)symptoms of hyperactivity, inattention, and impulsivity or hypothesized neuropsychological differences in children with fetal alcohol syndrome (FAS) and ADHD. Atomoxetine Hydrochloride is a non-stimulant medication used to treat ADHD. This study will determine if atomoxetine HCL significantly reduces symptoms of ADD/ADHD in children with fetal alcohol exposure.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Study of the Efficacy of Atomoxetine in Treating the Inattention, Impulsivity and Hyperactivity in Children With Fetal Alcohol Syndrome or Effects
Study Start Date : August 2005
Actual Primary Completion Date : April 22, 2015
Actual Study Completion Date : April 22, 2015

Arm Intervention/treatment
Active Comparator: 1
Atomoxetine HCL (Strattera)
Drug: Strattera
escalating dosage: 0.5 mg/kg, 1.0 mg/kg, and 1.4 mg/kg titrated up or down according to adverse effects to therapy
Other Name: atomoxetine HCL

Placebo Comparator: 2 Drug: Placebo
0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.

Primary Outcome Measures :
  1. ADHD Rating Scale - IV [ Time Frame: length of protocol ]

Secondary Outcome Measures :
  1. Determine if atomoxetine is safe and well tolerated by children with FAS. [ Time Frame: length of protocol ]
  2. Determine if atomoxetine is effective in both school and home, and significantly reduces symptoms of inattention, hyperactivity, and impulsivity in children with FAS compared to children with FAS receiving placebo. [ Time Frame: length of protocol ]
  3. Determine if atomoxetine improves behaviors in the mornings and evenings. [ Time Frame: Length of protocol ]
  4. Determine if parents of children with FAS are satisfied with the effectiveness of atomoxetine. [ Time Frame: Length of protocol ]
  5. Determine if there are any differences in the adverse effects profile of children with FAS compared to the overall profile for atomoxetine. [ Time Frame: Length of protocol ]
  6. Determine the degree of functional limitation experienced by this group of children with FAS and whether this impairment is decreased by treatment with atomoxetine as demonstrated by the Pediatric Evaluation of Disability Inventory (PEDI) [ Time Frame: Length of protocol ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   4 Years to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient must be between the ages of 4 and 11 years at the time of entry into the study.
  • Patients must meet diagnostic criteria for FASD
  • Patient must meet DSM-IV criteria for ADHD, any subtype and must have an ADHDRS-IV score of > or = to 90%ile for age and gender for either subtest or total score if greater than 5 years of age.
  • Patients who enter the study at visit 1 taking stimulant medication must be medication-free for at least 24 hours before visit 2.
  • History and physical exam must reveal no clinically significant abnormalities that would preclude safe participation in the study.
  • Patients must be able to swallow capsules.
  • Patients must be of a sufficient developmental level (~3 yrs) to participate in the study.
  • Patients and parents must be able to communicate effectively with the investigator and coordinator and be judged reliable to keep appointments and participate in data collection.
  • Teacher must agree to cooperate with the study. Children less than 6 years old must have completed a course of PCIT and still meet DSM-IV criteria for ADHD.

Exclusion Criteria:

  • Have received an in investigational medication in the past 30 days.
  • Are currently on a medication treatment that is effective (ADHDRS-IV score within 1 SD of average) and well tolerated.
  • Have significant current medical conditions that could be exacerbated or compromised by atomoxetine.
  • Have used MAOIs within one month prior to visit 2.
  • Patients with hypertension.
  • Patients with a previous diagnosis of bipolar disorder, psychosis, or autism spectrum disorder.
  • Patients taking anticonvulsants for seizure control.
  • Patients taking another psychotropic medication or health food supplements purported to have central nervous system activity within 5 half-lives of visit 2.
  • Patients with Tourette Disorder or any other neurological condition that would interfere with their ability to receive treatment or comply with monitoring.
  • Pubertal girls.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00417794

Layout table for location information
United States, Oklahoma
OU Child Study Center
Oklahoma City, Oklahoma, United States, 73117
Sponsors and Collaborators
University of Oklahoma
Mark L. Wolraich, M.D.
Eli Lilly and Company
Layout table for investigator information
Principal Investigator: Laura J McGuinn, PhD University of Oklahoma

Layout table for additonal information
Responsible Party: University of Oklahoma Identifier: NCT00417794     History of Changes
Other Study ID Numbers: 2115
First Posted: January 4, 2007    Key Record Dates
Last Update Posted: April 10, 2017
Last Verified: April 2017

Keywords provided by University of Oklahoma:
attention deficit hyperactivity disorder
fetal alcohol syndrome
atomoxetine hcl

Additional relevant MeSH terms:
Layout table for MeSH terms
Fetal Alcohol Spectrum Disorders
Fetal Diseases
Alcohol-Induced Disorders
Alcohol-Related Disorders
Attention Deficit Disorder with Hyperactivity
Pathologic Processes
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Pregnancy Complications
Substance-Related Disorders
Chemically-Induced Disorders
Atomoxetine Hydrochloride
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents